VERA Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to Vera Therapeutics's net margin of -49.65%. Vera Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Vera Therapeutics has a consensus price target of --, signalling upside risk potential of 52.64%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that NovaBay Pharmaceuticals has higher upside potential than Vera Therapeutics, analysts believe NovaBay Pharmaceuticals is more attractive than Vera Therapeutics.

Vera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Vera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Vera Therapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Vera Therapeutics's net income of -$46.6M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Vera Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

PROCEPT BioRobotics has a net margin of -- compared to Vera Therapeutics's net margin of -35.93%. Vera Therapeutics's return on equity of -- beat PROCEPT BioRobotics's return on equity of -37.42%.

Vera Therapeutics has a consensus price target of --, signalling upside risk potential of 52.64%. On the other hand PROCEPT BioRobotics has an analysts' consensus of $102.75 which suggests that it could grow by 26.62%. Given that Vera Therapeutics has higher upside potential than PROCEPT BioRobotics, analysts believe Vera Therapeutics is more attractive than PROCEPT BioRobotics.

Vera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison PROCEPT BioRobotics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Vera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. PROCEPT BioRobotics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics pays -- of its earnings as a dividend. PROCEPT BioRobotics pays out -- of its earnings as a dividend.

Vera Therapeutics quarterly revenues are --, which are smaller than PROCEPT BioRobotics quarterly revenues of $58.4M. Vera Therapeutics's net income of -$46.6M is lower than PROCEPT BioRobotics's net income of -$21M. Notably, Vera Therapeutics's price-to-earnings ratio is -- while PROCEPT BioRobotics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics is -- versus 20.84x for PROCEPT BioRobotics. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Vera Therapeutics's net margin of -2357.27%. Vera Therapeutics's return on equity of -- beat Palatin Technologies's return on equity of --.

Vera Therapeutics has a consensus price target of --, signalling upside risk potential of 52.64%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than Vera Therapeutics, analysts believe Palatin Technologies is more attractive than Vera Therapeutics.

Vera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Vera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Vera Therapeutics quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Vera Therapeutics's net income of -$46.6M is lower than Palatin Technologies's net income of -$7.8M. Notably, Vera Therapeutics's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -- compared to Vera Therapeutics's net margin of --. Vera Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Vera Therapeutics has a consensus price target of --, signalling upside risk potential of 52.64%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 6861.54%. Given that Theriva Biologics has higher upside potential than Vera Therapeutics, analysts believe Theriva Biologics is more attractive than Vera Therapeutics.

Vera Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.

Vera Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vera Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Vera Therapeutics quarterly revenues are --, which are smaller than Theriva Biologics quarterly revenues of --. Vera Therapeutics's net income of -$46.6M is lower than Theriva Biologics's net income of -$7.7M. Notably, Vera Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vera Therapeutics is -- versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.